GFAP and early-onset autosomal dominant Alzheimer disease: To determine the effects of sorafenib on neuroinflammatory responses in a mouse model of Alzheimer’s disease (AD), 5xFAD mice were treated with sorafenib (10 mg/kg/day, i.p.)or vehicle daily for 3 consecutive days, and immunofluorescence staining were conducted with an anti-Iba-1 or anti-GFAP antibody (Figure 8A).